An intervention to reduce stigma and improve management of depression, risk of suicide/self-harm and other significant emotional or medically unexplained complaints among adolescents living in urban slums: protocol for the ARTEMIS project.

Adolescent mental health Anti-stigma campaign Depression and increased risk of self-harm/suicide Electronic decision support systems India Other significant emotional or medically unexplained complaints Primary healthcare worker Randomised control trial Slums

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
29 Jul 2022
Historique:
received: 26 04 2022
accepted: 11 07 2022
entrez: 29 7 2022
pubmed: 30 7 2022
medline: 3 8 2022
Statut: epublish

Résumé

There are around 250 million adolescents in India. Adolescents are vulnerable to common mental disorders with depression and self-harm accounting for a major share of the burden of death and disability in this age group. Around 20% of children and adolescents are diagnosed with/ or live with a disabling mental illness. A national survey has found that suicide is the third leading cause of death among adolescents in India. The authors hypothesise that an intervention involving an anti-stigma campaign co-created by adolescents themselves, and a mobile technology-based electronic decision support system will help reduce stigma, depression, and suicide risk and improve mental health for high-risk adolescents living in urban slums in India. The intervention will be implemented as a cluster randomised control trial in 30 slum clusters in each of the cities of Vijayawada and New Delhi in India. Adolescents aged 10 to 19 years will be screened for depression and suicide ideation using the Patient Health Questionnaire (PHQ-9). Two evaluation cohorts will be derived-a high-risk cohort with an elevated PHQ-9 score ≥ 10 and/or a positive response (score ≥ 2) to the suicide risk question on the PHQ-9, and a non-high-risk cohort comprising an equal number of adolescents not at elevated risk based on these scores. The key elements that ARTEMIS will focus on are increasing awareness among adolescents and the slum community on these mental health conditions as well as strengthening the skills of existing primary healthcare workers and promoting task sharing. The findings from this study will provide evidence to governments about strategies with potential for addressing the gaps in providing care for adolescents living in urban slums and experiencing depression, other significant emotional or medically unexplained complaints or increased suicide risk/self-harm and should have relevance not only for India but also for other low- and middle-income countries. Protocol version - V7, 20 Dec 2021 Recruitment start date: tentatively after 15th July 2022 Recruitment end date: tentatively 14th July 2023 (1 year after the trial start date) TRIAL REGISTRATION: The trial has been registered in the Clinical Trial Registry India, which is included in the WHO list of Registries ( https://www.who.int/clinical-trials-registry-platform/network/primary-registries ) Reference No. CTRI/2022/02/040307 . Registered on 18 February 2022. The tentative start date of participant recruitment for the trial will begin after 15th July 2022.

Sections du résumé

BACKGROUND BACKGROUND
There are around 250 million adolescents in India. Adolescents are vulnerable to common mental disorders with depression and self-harm accounting for a major share of the burden of death and disability in this age group. Around 20% of children and adolescents are diagnosed with/ or live with a disabling mental illness. A national survey has found that suicide is the third leading cause of death among adolescents in India. The authors hypothesise that an intervention involving an anti-stigma campaign co-created by adolescents themselves, and a mobile technology-based electronic decision support system will help reduce stigma, depression, and suicide risk and improve mental health for high-risk adolescents living in urban slums in India.
METHODS METHODS
The intervention will be implemented as a cluster randomised control trial in 30 slum clusters in each of the cities of Vijayawada and New Delhi in India. Adolescents aged 10 to 19 years will be screened for depression and suicide ideation using the Patient Health Questionnaire (PHQ-9). Two evaluation cohorts will be derived-a high-risk cohort with an elevated PHQ-9 score ≥ 10 and/or a positive response (score ≥ 2) to the suicide risk question on the PHQ-9, and a non-high-risk cohort comprising an equal number of adolescents not at elevated risk based on these scores.
DISCUSSION CONCLUSIONS
The key elements that ARTEMIS will focus on are increasing awareness among adolescents and the slum community on these mental health conditions as well as strengthening the skills of existing primary healthcare workers and promoting task sharing. The findings from this study will provide evidence to governments about strategies with potential for addressing the gaps in providing care for adolescents living in urban slums and experiencing depression, other significant emotional or medically unexplained complaints or increased suicide risk/self-harm and should have relevance not only for India but also for other low- and middle-income countries.
TRIAL STATUS METHODS
Protocol version - V7, 20 Dec 2021 Recruitment start date: tentatively after 15th July 2022 Recruitment end date: tentatively 14th July 2023 (1 year after the trial start date) TRIAL REGISTRATION: The trial has been registered in the Clinical Trial Registry India, which is included in the WHO list of Registries ( https://www.who.int/clinical-trials-registry-platform/network/primary-registries ) Reference No. CTRI/2022/02/040307 . Registered on 18 February 2022. The tentative start date of participant recruitment for the trial will begin after 15th July 2022.

Identifiants

pubmed: 35906663
doi: 10.1186/s13063-022-06539-8
pii: 10.1186/s13063-022-06539-8
pmc: PMC9336093
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

612

Subventions

Organisme : Medical Research Council
ID : MR/S023224/1
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Lancet. 2018 Oct 27;392(10157):1553-1598
pubmed: 30314863
Indian J Psychiatry. 2017 Jan-Mar;59(1):46-55
pubmed: 28529360
Psychol Med. 2013 Aug;43(8):1569-85
pubmed: 22883473
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
J Affect Disord. 2011 Dec;135(1-3):267-76
pubmed: 21890209
Lancet. 2017 Jan 14;389(10065):176-185
pubmed: 27988143
Psychol Med. 2017 Feb;47(3):565-575
pubmed: 27804895
BMJ Paediatr Open. 2017 Oct 25;1(1):e000139
pubmed: 29637154
Lancet. 2009 Jan 31;373(9661):408-15
pubmed: 19162314
Int J Bipolar Disord. 2014 Jan 21;2:1
pubmed: 25505692
Int J Ment Health Syst. 2011 Aug 05;5(1):17
pubmed: 21819562
J Postgrad Med. 2007 Apr-Jun;53(2):102-7
pubmed: 17495375
Lancet. 2016 Mar 12;387(10023):1123-1132
pubmed: 26410341
JAMA. 2004 Jun 2;291(21):2581-90
pubmed: 15173149
Indian J Community Med. 2013 Jan;38(1):22-6
pubmed: 23559699
Indian J Psychiatry. 2017 Jan-Mar;59(1):21-26
pubmed: 28529357
World Psychiatry. 2002 Feb;1(1):16-20
pubmed: 16946807
Glob Ment Health (Camb). 2015 Jul 29;2:e13
pubmed: 28596861
Br J Psychiatry. 2007 Mar;190:192-3
pubmed: 17329736
Lancet. 2012 Jun 23;379(9834):2343-51
pubmed: 22726517
Implement Sci. 2011 Aug 03;6:87
pubmed: 21824381
PLoS Med. 2012;9(12):e1001359
pubmed: 23300387
Br Med Bull. 2010;96:5-21
pubmed: 21037243
J Adolesc Health. 2016 Oct;59(4S):S49-S60
pubmed: 27664596
Br J Psychiatry. 2011 Dec;199(6):459-66
pubmed: 22130747
Int J Epidemiol. 2017 Dec 1;46(6):2036-2043
pubmed: 28666347
World Psychiatry. 2004 Feb;3(1):3-5
pubmed: 16633441
Lancet Psychiatry. 2020 Feb;7(2):148-161
pubmed: 31879245
PLoS Med. 2013;10(1):e1001363
pubmed: 23458994
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
J Med Internet Res. 2020 Feb 27;22(2):e15553
pubmed: 32130125
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
JMIR Mhealth Uhealth. 2018 Oct 26;6(10):e11440
pubmed: 30368435
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
J Glob Health. 2017 Jun;7(1):010408
pubmed: 28400954
BMJ. 2005 Apr 2;330(7494):765
pubmed: 15767266
Int J Ment Health Syst. 2018 Aug 18;12:47
pubmed: 30140307
J Health Econ. 2002 Mar;21(2):271-92
pubmed: 11939242
Pediatrics. 2010 Dec;126(6):1117-23
pubmed: 21041282
Psychiatr Serv. 2012 Oct;63(10):963-73
pubmed: 23032675
PLoS One. 2016 Oct 12;11(10):e0164404
pubmed: 27732652

Auteurs

Sandhya Kanaka Yatirajula (SK)

The George Institute for Global Health, New Delhi, India.

Sudha Kallakuri (S)

The George Institute for Global Health, New Delhi, India.

Srilatha Paslawar (S)

The George Institute for Global Health, New Delhi, India.

Ankita Mukherjee (A)

The George Institute for Global Health, New Delhi, India.

Amritendu Bhattacharya (A)

The George Institute for Global Health, New Delhi, India.

Susmita Chatterjee (S)

The George Institute for Global Health, New Delhi, India.

Rajesh Sagar (R)

All India Institute of Medical Sciences, New Delhi, India.

Ashok Kumar (A)

Dr.A.V. Baliga Memorial Trust, New Delhi, India.

Heidi Lempp (H)

Department of Inflammation Biology, Centre for Rheumatic Diseases, Faculty of Life Sciences & Medicine, King's College London, London, UK.

Usha Raman (U)

University of Hyderabad, Hyderabad, India.

Renu Singh (R)

Young Lives India, New Delhi, India.

Beverley Essue (B)

Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

Laurent Billot (L)

The George Institute for Global Health, Sydney, Australia.
University of New South Wales, Sydney, Australia.

David Peiris (D)

The George Institute for Global Health, Sydney, Australia.
University of New South Wales, Sydney, Australia.

Robyn Norton (R)

The George Institute for Global Health, Sydney, Australia.
University of New South Wales, Sydney, Australia.
Imperial College, London, UK.

Graham Thornicroft (G)

Centre for Global Mental Health and Centre for Implementation Science, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Pallab K Maulik (PK)

The George Institute for Global Health, New Delhi, India. pmaulik@georgeinstitute.org.in.
University of New South Wales, Sydney, Australia. pmaulik@georgeinstitute.org.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH